Miami Regenerative Medicine: The SB 1768 Vetting Framework for 2026

Introduction: Why Miami Regenerative Medicine Searches Need a Regulatory Lens in 2026

Searches for stem cell therapy, platelet-rich plasma (PRP), exosomes, and bone marrow aspiration concentrate (BMAC) across the Miami area have climbed steadily. Patients with worn knees, torn rotator cuffs, chronic back pain, and stubborn tendon injuries want options that do not involve an operating room. The supply of clinics has grown to meet that demand, but the explanation of the rules governing those clinics has not kept pace.

That gap matters because Florida now has a specific law on the books. SB 1768, effective July 1, 2025, and codified as Fla. Stat. §458.3245 and §459.0127, is the state’s first law explicitly authorizing physician-directed stem cell therapy for orthopedic, wound care, and pain management conditions. It sets sourcing rules, facility requirements, and felony penalties for certain violations.

Most Miami clinic websites sell treatments and outcomes without explaining any of this. Patients are asked to consent to procedures without understanding the legal framework those procedures are supposed to follow.

This article makes two promises:

1. A practical, law-based vetting checklist that separates legitimate providers from red-flag marketing.
2. An honest look at geography: whether Miami is the best place to receive care, or whether a 45 to 60 minute trip to a more rigorously credentialed provider is the smarter trade-off.

The stakes are rising. The global regenerative medicine market is estimated in the $48 to $80 billion range for 2026, depending on methodology, with most forecasts projecting 16% to 25% compound annual growth into the early 2030s. Markets that grow this quickly attract both serious practitioners and opportunists, which makes scrutiny matter more than ever.

What SB 1768 Actually Authorizes, and What It Doesn’t

SB 1768 is frequently misunderstood as a blanket legalization of stem cell therapy in Florida. It is not. The law is a narrow, physician-directed authorization, and it does not validate every marketing claim a clinic chooses to make.

The statute applies to three specific categories:

• Orthopedic conditions
• Wound care
• Pain management

The therapy must be performed by a licensed allopathic (MD) or osteopathic (DO) physician. Florida’s legislative analysis describes the bill as authorizing these physicians to perform stem cell therapies not approved by the FDA within those defined areas. The law also includes informed consent and advertising requirements. A clinic promising stem cell treatment for autism, neurological disease, or anti-aging outside those boundaries is not operating under the protection SB 1768 provides.

Ethical Sourcing Rules and Felony Penalties

The sourcing rules are among the law’s most important provisions. Under SB 1768, stem cells must be derived from umbilical cord or placental tissue obtained from live births.

The law explicitly bans cells derived from embryonic tissue or aborted fetal tissue, including umbilical-derived cells from abortions. Violations of these sourcing restrictions constitute a third-degree felony in Florida.

This turns cell origin into a meaningful legal risk signal rather than a minor detail. A clinic that is vague about where its cells come from may not simply be unclear in its marketing; it may be non-compliant with state law. Patients have every reason to treat evasiveness on this point as disqualifying.

FDA-Registered, Accredited Facility Requirements

SB 1768 also requires that stem cell products come from a facility that is registered with the FDA and certified or accredited by one of four designated accrediting organizations named in the statute.

This requirement creates a traceable paper trail. A compliant clinic should be able to identify:

• The name of the source facility
• Its FDA registration status
• The accrediting organization that certifies it

Few safeguards in regenerative medicine are this concrete. Clinical outcomes are hard for patients to evaluate on their own, but a facility’s registration and accreditation can be verified. Patients can and should request this documentation before agreeing to treatment.

The FDA Reality Check: What Regenerative Medicine Still Isn’t Approved For

State authorization does not equal federal approval. The FDA has not approved stem cell, PRP, or exosome products for orthopedic or pain conditions. According to the CDC, the only FDA-approved stem cell treatments are products that treat certain cancers and disorders of the blood and immune system.

Most regenerative treatments offered in Miami clinics are therefore delivered as physician-directed or off-label care. SB 1768 creates a state-level pathway for that use within defined limits, but it does not override federal oversight.

Federal authority remains active. A 2024 federal court ruling upheld the FDA’s authority to regulate both minimally manipulated and more-than-minimally manipulated cell products. Florida patients are therefore protected, and providers are bound, by two regulatory layers at once: state law governing physician practice and sourcing, and federal law governing the products themselves.

Documented Risks of Unapproved or Unregulated Products

The regulatory framework exists for good reason. The FDA has issued a public safety alert describing multiple reports of serious adverse events in patients treated with unapproved products marketed as containing exosomes. The FDA and CDC have documented harms tied to unapproved stem cell and exosome products, including:

• Bloodstream infections
• Blindness
• Tumors
• Rare cases of death

The Pew Charitable Trusts has separately documented serious and sometimes lifelong harms linked to unapproved stem cell interventions nationally, including partial or complete blindness, paraplegia, pulmonary embolism, cardiac arrest, and tumors or other abnormal growths.

The Federal Trade Commission has also acted against clinics making deceptive claims that stem cells can treat conditions such as Parkinson’s disease, autism, and macular degeneration. That enforcement is a reminder that a marketing claim is only a claim. It is not evidence, and it is not regulatory approval.

The SB 1768 Patient Vetting Checklist

This section is the practical core of the article. The checklist below translates SB 1768’s statutory requirements, along with federal regulatory realities, into questions any patient can bring to a Miami-area consultation. It is built on the specific requirements of Florida law, not on generic wellness advice.

1. Physician Credentialing Verification

SB 1768 is a physician-directed framework, so the first check is who is actually responsible for care.

• Confirm the treating provider is a licensed MD or DO. A practice run solely by a chiropractor, naturopath, or unsupervised mid-level provider does not fit the law’s structure.
• Verify licensure and board certification. Florida’s Department of Health license lookup shows a physician’s license status and any public disciplinary history. Board certification can be confirmed through the relevant specialty board.
• Ask who performs the injection and who merely supervises. Some clinics list a physician as “medical director” while other staff handle every procedure. Patients deserve a direct answer about who will be in the room and who is accountable.

2. Cell-Source Documentation

The sourcing rules carry felony penalties, so documentation is not optional.

• Request written proof that cells originate from umbilical cord or placental tissue from live births.
• Treat vague sourcing language as a red flag. Terms such as “proprietary,” “advanced,” or “next-gen” mean little without a named, verifiable tissue bank or supplier.
• Expect a direct answer. A legitimate clinic should be able to name its FDA-registered, accredited source facility without hesitation. Delays, deflection, or claims that the information is confidential warrant serious caution.

3. Imaging-Guided Injection Technology

Placement accuracy affects both safety and results. Image guidance with ultrasound or fluoroscopy (X-ray) is widely regarded as a clinical standard for precise joint and soft-tissue injections.

• Flag “blind” injections performed without imaging, particularly for deep or complex targets such as the hip or spine, where anatomy is difficult to reach accurately by feel alone.
• Ask specifically which imaging technology will be used during the patient’s own procedure. “We offer ultrasound” is not the same as “your injection will be ultrasound-guided.”

4. FDA-Compliance Disclosures

Transparent providers disclose the regulatory status of what they offer.

• Look for a clear statement that stem cell, PRP, and exosome products are not FDA-approved for orthopedic use and that treatment is offered within a physician-directed, off-label framework under SB 1768.
• Treat implied FDA approval as a significant red flag. Leaving the disclosure out entirely is just as concerning.
• Review the informed consent document. It should reference both the Florida statute and the federal regulatory status of the treatment. A consent form that mentions neither falls short of the transparency the law contemplates.

Red Flags: Miami Marketing Language That Signals Risk

Miami’s regenerative medicine market is crowded, and competition tends to inflate the language. Certain patterns signal that marketing is standing in for verifiable credentials:

• Superlative promises. Phrases such as “miracle healing,” “revolutionary cure,” and “guaranteed results” are incompatible with the evidence base and the regulatory status of these therapies.
• Testimonials without evidence. Patient stories can be genuine, but a website built mainly on testimonials, with no citation of clinical research and no regulatory disclosures, is selling emotion rather than information.
• Unverifiable volume and exclusivity claims. Titles like “Florida’s Leader,” large procedure counts with no source, and branded exclusive-access products tell patients little about credentialing, sourcing, or safety.
• Borrowed academic prestige. Miami has real research credibility. The University of Miami Miller School of Medicine operates the Interdisciplinary Stem Cell Institute and the Diabetes Research Institute’s Cell Transplant Center. These are academic research environments with institutional oversight. A commercial clinic that happens to be in the same city does not inherit that oversight, and patients should not let the city’s research reputation stand in for a specific clinic’s credentials.

What the Evidence Actually Supports, and What It Doesn’t

The evidence for regenerative medicine is real but bounded, and honest providers say so.

For PRP, the data are strongest in knee osteoarthritis. Multiple peer-reviewed meta-analyses published between 2024 and 2026, including an umbrella meta-analysis and a comprehensive narrative review indexed in major medical literature databases, show that PRP injections outperform hyaluronic acid and placebo for pain and function in mild-to-moderate knee osteoarthritis. Leukocyte-poor PRP appears to perform especially well.

The caveats matter just as much:

• Long-term efficacy data beyond 6 to 12 months remain inconsistent.
• GRADE evidence certainty is rated only “moderate.”

Stem cell therapies are earlier in development. Approximately 224 clinical trials worldwide are investigating stem cell therapies for osteoarthritis, and a $140 million Phase III trial was announced in January 2026. That activity points to a maturing field, but it does not make the question settled.

Patients should therefore expect realistic, evidence-bounded claims. A provider who explains what the data show, where they fall short, and why a given patient may or may not be a good candidate is far more trustworthy than one who guarantees surgery avoidance.

Miami vs. the Smarter Trade-Off: Is a 45-60 Minute Trip Worth It?

Most patients frame the decision as “which Miami clinic should I choose?” A more useful question comes first: is Miami the right geographic choice at all?

Miami’s academic credibility in regenerative science is genuine, but patients seeking orthopedic regenerative care are usually not enrolling in university research. They are choosing among commercial clinics, and that landscape varies widely in transparency, credentialing, and sourcing disclosure. Proximity is convenient, but it is not a credential.

The Boca Raton Alternative: Multi-Modality, Imaging-Guided Care

Unicorn Bioscience’s Boca Raton location, at 200 Glades Rd #2, shows what transparent, multi-modality regenerative care can look like. The practice offers:

• Stem cell therapy
• PRP (platelet-rich plasma)
• BMAC (bone marrow aspiration concentrate)
• Exosome therapy
• Hyaluronic acid injections
• Peptide therapy

That breadth matters because the right treatment depends on the patient. Protocols are personalized around inflammation levels, age, injury type and location, current medications, and personal health goals, so the clinic is not steering every patient toward a single modality.

All injections are administered with ultrasound or X-ray imaging guidance, which meets the precision standard described in the checklist. The practice also discloses publicly that, as of 2026, the FDA has not approved stem cell, PRP, or exosome products specifically for orthopedic conditions. That is the kind of disclosure patients should expect everywhere.

The team’s credentials offer a useful benchmark. CEO and founder Dr. Aldaas is a board-certified physician with more than a decade in hospital medicine and a former Assistant Professor of Medicine at Albany Medical Center. Technical manager Josh Simpson, MS-PAC, trained in orthopedic surgery at Johns Hopkins and brings hands-on experience in orthopedic trauma from his clinical training. Patients should look for this kind of verifiable training wherever they seek care.

Accessibility also factors in. Qualified candidates can receive same-day treatment following their consultation, and virtual consultations let Miami residents begin an evaluation before traveling at all.

Drive Time, Brightline, and the Quality Calculus

The trip is shorter than many patients assume:

• By car: approximately 44 to 46 miles, with drive times from about 46 minutes to over an hour depending on traffic.
• By Brightline: a direct, hourly train connects Miami and Boca Raton in roughly 51 minutes.

Seen this way, the commute is a reasonable trade-off. It buys access to documented credentialing, imaging-guided procedures, transparent regulatory disclosure, and a wider range of treatment options than single-modality practices offer.

Boca Raton’s demographics help explain why this model works there. The city has a median household income above $100,000, a median age in the mid-40s, and a senior population share well above Florida’s statewide average. Most regenerative treatments are cash-pay because they generally lack insurance reimbursement, and markets like Boca Raton support a more deliberate, consultation-driven practice model.

To be balanced: Miami is not inherently worse. Excellent providers may practice there. The point is that the same SB 1768 checklist applies in every city, and geographic convenience should never override credentialing and sourcing verification.

Applying the Framework: A Step-by-Step Vetting Walkthrough

Before booking any consultation in Miami, Boca Raton, or elsewhere, patients can work through this sequence:

1. Verify the physician’s license through the Florida Department of Health and confirm board certification.
2. Request source facility documentation, including FDA registration and accreditation.
3. Confirm the imaging technology that will be used for the specific procedure.
4. Review the informed consent form for disclosures on both FDA status and SB 1768.
5. Cross-check marketing claims against cited clinical evidence.

Questions to ask during the consultation call:

• “Is the treating provider a licensed MD or DO, and will that physician perform or directly supervise my injection?” (SB 1768’s physician-directed requirement)
• “What is the name of your cell source facility, and can you provide documentation of its FDA registration and accreditation?” (SB 1768’s facility requirement)
• “Can you confirm in writing that the cells come from umbilical cord or placental tissue from live births?” (SB 1768’s sourcing rules and felony provisions)
• “Will my procedure be guided by ultrasound or fluoroscopy?” (Clinical precision standard)
• “Does your consent form explain that this treatment is not FDA-approved for my condition?” (Federal regulatory status)
• “What does the published evidence show for my condition, and what are its limitations?” (Evidence-bounded claims)

A legitimate provider will welcome these questions and answer them directly. Evasiveness is itself an answer.

Conclusion: Regulatory Literacy Is the New Patient Advocacy

SB 1768 is genuine progress. It gives Florida patients a defined path to physician-directed regenerative therapy for orthopedic, wound care, and pain conditions. That progress only protects patients when the sourcing, accreditation, and disclosure rules are actually followed.

The four-part checklist is the patient’s primary defense against red-flag marketing:

1. Physician credentialing
2. Cell-source documentation
3. Imaging-guided injection
4. FDA-compliance disclosure

The “where” question matters as much as the “who” question. A short trip to a more rigorously credentialed, multi-modality provider can be a rational, evidence-based choice. In a market growing faster than oversight can always keep pace, informed vetting is what separates good outcomes from avoidable harm.

Ready to Evaluate Your Options? Start With a Credentialed Consultation

Patients are encouraged to apply the SB 1768 checklist to any clinic they are considering, whether in Miami or anywhere else in South Florida.

For those who want to experience imaging-guided, multi-modality, physician-led evaluation firsthand, Unicorn Bioscience’s Boca Raton location offers both virtual and in-person consultations.

• Location: 200 Glades Rd #2, Boca Raton, FL 33432
• Phone: (737) 347-0446
• Website: unicornbioscience.com

The trip from Miami takes roughly 46 minutes by car in normal traffic or about 51 minutes on Brightline’s direct hourly service, and a virtual consultation can come first.

Informed patients tend to have better, safer outcomes, and asking the right questions costs nothing.